The purpose of this study was to determine the charges for radiofrequency catheter modification of the atrioventricutar (AV) node in 15 patients with symptomatic AV node reentrant tachycardia despite pharmacologic therapy and to compare these charges with the estimated charges for health care utilization by the same patients before the catheter procedure was performed . There were seven men and eight women with a mean age of 50 17 years. The mean duration and frequency of symptoms were 16 t 9 years and 4.5 t 6 episodes/month, respectively. Fourteen of the 15 patients required only one procedure for diagnosis and cure of AV node reentrant tachycardia and I patient required two sessions . All patients underwent electrophysiologic study before discharge from the hospital to confirm the short-term efficacy of the procedure.
$15,893 t $3,338 for catheter modification . These total charges consr1ed of hospital charges of $8,105 ± $2,466 and physician charges of $7,788 A $971. All patients had a successful outcome and required no additional antiarrhythmic therapy . The estimated cost of health rare utilization for these 15 patients before cure of AV node reentrant tachycardia was $7,tSVpatient per year . These estimated costs included charges incurred for energency room visits, office visits, hospitalizations and antiarrhythmic drug therapy.
In conclusion, the results of this study indicate that the annual health care costs incurred by patients who have symptomatic, dog-refractory paroxysmal sapraventricutar tachycardia caused by AV node reentry are substantial . Radiofrequency catheter modification of the AV node not only is of clinical benefit, but also results in a dramatic long-term reduction in medical expenses .
(J .4m Call Cardinl 1992;I9:1583- 7) ular tachycardia are clear, the economic impact of curing this form of tachycardia by radiofrequency modification of the AV node in patients with drug-refractory AV node reentrant tachycardia has not been previously analyzed . Therefore, the purpose of this study was to determine the cost of radiofrequency modification of the AV node in a group of patients with a long history of symptomatic paroxysmal supraventricufar tachycardia despite pharmacologic therapy and to compare this cost with the medical expenses incurred before the procedure as a result of the tachycardia.
Methods
Study design . This was a retrospective study of 15 patients who underwent successful radiofrequency catheter modification of the AV node for treatment of AV node reentrant tachycardia at the University of Michigan Medical Center between January and July 1990 . Radiofrequency catheter ablation was performed under a protocol approved by the Human Research Committee at the University of Michigan after informed written consent was obtained from all patients . Patients were selected for analysis if they had had a successful outcome of catheter modification of the AV KALBFLEISCH ET AL . COST OF THERAPY FOR AV NODE REENTRANT TACHYCARDIA node after unsuccessful pharmaeologic therapy and if they were available for questioning by telephone . Hospital billing records were reviewed to determine the hospital and physician charges related to the catheter modification procedure . Records were reviewed and all patients were contacted by telephone to determine the duration and frequency of symptoms, number and type of prior antiarrhythmic medications, symptoms related to the tachycardia, presence of structural heart disease, prior use of health care facilities (including emergency room visits, office visits and hospital admissions) and the number of days missed from work as a result of the tachycardia.
Patient characteristics . There were seven men and eight women with a mean age (±SD) of 50 ± 17 years. Thirteen patients had no structural heart disease and two had coronary artery disease. The mean duration and frequency of symptoms were 16 ± 9 years • :md 4 .5 ± 6 episodes/month, respectively. The patients had been unsuccessfully treated with a mean of 2 .4 ± 1 .4 antiarrhythmic medications . Digoxin had been used in 7 patients, verapamil in 10, a beta-adrenergic blocking agent in 8, quinidine in 7 and flecainide in 2 . Each patient continued to have symptomatic tachycardia despite drug therapy and 9 of 15 patients experienced medication side effects . During the tachycardia, 14 patients had rapid palpitation, 10 had light-headedness, 8 had chest pain, 8 had shortness of breath and 3 had syncopal episodes.
Catheter ablation procedure . All patients underwent the initial electrophysiologic procedure with the intent of diagnosis and cure during the same session (4) . The technique utilized in these 15 patients, ablation of the retrograde fast pathway of the AV node reentrant tachycardia circuit, has previously been described (4, 5) . After the ablation procedure, patients underwent continuous telemetric electrocarrliographic (ECG) monitoring in the hospital and underwent electrophysiologic study 2 days after the procedure, before hospital discharge, to confirm the short-term efficacy of the procedure . If AV node reentrant tachycardia was inducible, AV node modification was attempted again and another electrophysiologic study was performed 24 to 48 h later . A daily 12-lead ECO was obtained and creatine kinase and its MB fraction were measured every 8 h for 24 h after the procedure .
Catheter modification charg.-e. Hospital billing records were reviewed to determine the hospital a,td professional charges during the hospital admission in which the electrophysiologic procedure was performed . All charges that were related to management of the patient's AV node reentrant tachycardia during this hospital stay were included . These charges included all ECG studies, blood tests, chest X-ray films, echocardiograms, medications and electrophysiologic studies . Charges unrelated to management of the patient's tachycardia were excluded .
Prior medical expenses . Charges for office visits, emergency room visits and hospital admissions were based on billing fees at the University of Michigan and were adjusted JACC Vol . 19, Na . 7
June 1992:1593-7 Table 1 . Annual Retail Cost of Various Antiarrhythmic Medications bid = twice a day : qd = once a day; qid = four times a day : lid = three times a day.
to 1991 dollar values . It was assumed that office visits were of intermediate length and did not include an ECG . Emergency room visits were assumed to be 1 .5 to 2 h in duration, with one 12-lead ECG and 5 mg of intravenous verapamil for termination of the tachycardia. The typical hospital stay was estimated to have a duration of 2 days and to include continuous telemetric ECG monitoring, a 12-lead ECG, basic laboratory work and 5 mg of intravenous verapamil . The estimated charges for office visits, emergency room visits and hospital admissions were $70, $821 and $2,219, respectively .
Total estimated charges for emergency room and office visits/patient per year were based on the mean number of office and emergency room visits for the group of 15 patients during the year before cure of the AV node reentrant tachycardia . The estimated charge for hospitalizations was calculated by using the mean number of hospitalizations/ patient per year for the total duration of tachycardia symptoms . Medication charges were determined from the outpatient pharmacy at the University of Michigan Hospitals and were based on a 1-month refill schedule (Table I ) . The antiarrhythmic medications and dosages chosen for cost analysis were those that were typically used by the patients and are available at the University of Michigan outpatient pharmacy. The estimated charges/patient per year for medications were calculated by using a weighted average of the cost of each antiarrhythmic drug used .
Results
The cumulative annual expenses incurred by patients with paroxysmal supraventricular tachycardia due to AV node reentry and the cumulative charges associated with various types of therapy are shown in Figure I .
AV node modification. The age of the patients, number of electrophysiologic studies performed, days of hospital stay, hospital charges, physician charges and total charges are listed in Table 2 . The mean total charge for cur .
-r AV node reentrant tachycardia, $15,893 ± $3,338, comprised hospital charges of $8,105 ± $2,466 and physician charges of $7,788 ± $971 . The majority of hospital charges consisted of the electrophysiologic laboratory fee and the daily room charge for a monitored bed . Physician charges consisted primarily of professional fees for the electrophysiologic studies . Of the 15 patients, only I required two electrophysiologic, proce- node reentrant tachycardia at some time in the past . The two patients with underlying coronary artery disease had had the greatest number of hospital admissions related to episodes of tachycardia: 15 admissions at an estimated cost of $33,285 in one and 10 admissions at an estimated cost of $27,190 in the other.
Discussion
The main finding of this study is that symptomatic, drug-refractory AV node reentrant tachycardia is an expensive disorder to manage and that radiofrequency catheter modification of the AV node is a cost-effective form of therapy. Although the short-term cost of the procedure is high relative to the cost of antiarrhythmic medications, over the long-term the procedure results in significant cost savings in patients who continue to have episodes of paroxysmal supraventrieular tachycardia that do not terminate spontaneously .
Comparison with surgical therapy . Cryosurgery or surgical dissection in the vicinity of the AV node can eliminate AV node reentrant tachycardia (6, 7) . However, the catheter approach can cure AV node reentrant tachycardia at a cost that is less than one third that of the surgical approach . At the University of Michigan, the total charges for surgical therapy of supraucotricular tachycardia due r, the WolffParkinson-White syndrome in uncomplicated cases adjusted to 1991 dollar values were $53,174 ± $4,292 and consisted of hospital charges of $37,506 *_ $4 .076 and professional charges of $15,668 ± $1,501 (8) . From the standpoint of hospital charges and professional fees. the surgical treatment of AV node reentrant tachycardia raouid be expected to be similar to that of the Wolff Parkinson-White syndrome . Patients who underwent cryosurgery for AV node reentrant tachycardia were not used in this analysis because the few patients who underwent this procedure at our institution also underwent other surgical procedures . Nevertheless, it is clear that the catheter modification approach offers a significant cost advantage over the anticipated cost of surgical therapy for AV node reentrant tachycardia.
Comparison with other therapies . Antitachycardia pacing also has been used to treat drug-resistant supraventricular 7 .651 0 8.496 tachycardia. A recent study by Li et al. (9) demonstrated that the use of antitachycardia pacing for paroxysmal supraventricular tachycardia reduced the monthly medical charges from $505 ± $833 before pacemaker implantation to $105 ± $1 i7 after implantation, equivalent to a reduction in the mean annual cost from $6,060 to $1,260. In that study, in which charges were expressed in 1987 dollars, the charge for pacemaker implantation was $19,063 ± $8,362, not including pacemaker follow-up charges . Therefore, in addition to obviating the need for pacemaker implantation and followup, radiofrequency modification of the AV node is less expensive than antitachycardia pacing.
Complete ablation of the AV node and implantation of a permanent pacemaker is another possible form of therapy for AV node reentrant tachycardia . In a study by Rosengvist ct al . (10) , 26% of patients who underwent catheter ablation of the AV junction with direct current shocks had AV node reentrant tachycardia. After the ablation procedure, hospital admissions decreased from a mean of 2 .4 to 0.31year . The cost of this procedure was not specified, but would include the cost of the ablation procedure plus the cost of a dualchamber pacemaker, which in itself carries an initial implantation cost of approximately $16,000 at our institution . Therefore, catheter ablation of the AV junction is less cost-effective than radiofrequency catheter modification of the AV node in patients with AV node rccatrant tachycardia . Aside from economic considerations, catheter ablation of the AV junction, because it results in pacemaker dependency, should have only a very limited role in the management of patients with AV node reentrant tachycardia .
Comparison with effective pharmacologie therapy . In patients who have paroxysmal supraventricular tachycardia refractory to medical treatment and require frequent emergency room visits or hospitalizations, the economic advantage of definitive therapy is clear . However, in patients whose tachycardia is effectively controlled by medications, the cost-effectiveness of catheter modification is less clear . Table I lists the annual cost of several antiarrhythmic medications used to treat AV node reentrant tachycardia . In young patients who require the more expensive medications, such as verapamil, flecainide or quinidine gluconate, the catheter procedure may be justified from a cost standpoint because the cumulative cost of these medications would equal the cost of the catheter modification procedure within approximately 20 to 30 years . In addition, if the patient has a yearly office visit and ECG, the incremental cost would be approximately $1701year, making catheter modification an even more attractive alternative from a cost standpoint, Limitations. The major limitation of this study is an inherent selection bias . All patients in this study had not responded to medical therapy ; most were severely symptomatic and required multiple emergency room visits and hospital admissions. Therefore, the cost of medical care incurred by these patients may not be representative of those incurred by the typical patient who continues to experience episodes of paroxysmal supraventricular tachycardia despite pharmacologic therapy. For example, if a patient required only one emergency room visit each year plus basic periodic follow-up and medications, the estimated annual medical expenses would be $1,501, only 20% of the annual medical expenses of the patients in this study . However, even in this type of patient, the health care costs would exceed $15,000 in 10 years, making the catheter modification procedure cost-effective over the long-term .
In the two largest series of patients treated with the catheter modification procedure (4, 5) , the combined overall long-tern success rate for treating typical AV node reentrant tachycardia was 89% . Thus, in up to 11% of patients, the catheter modification charges may be incurred without curing the AV node reentrant tachycardia.
Although no patient in this study had a complication during the hospital stay, radiofraquency modification of the AV node may result in complete AV block . When the two largest reported series (4, 5) were considered together, this complication occurred in 4 (4 .7%) of 85 patients . Implantation of a permanent pacemaker carries an initial implantation charge of up to $16,000 . This could approximately double the overall charges in up to 5% of patient .; undergoing :diefrequency modification of the AV node with the technique used in this study .
The cost analysis in this study applies to patients who have paroxysmal supeaventricular tachycardia caused by AV node reentrant tachycardia . Although ECG findings may suggest that AV node reentry is present, electrophysiologic study is usually required to define the mechanism of paroxysmal supraventricular tachycardia . Therefore, Inless the patient has undergone electrophysiologic study-it may be unclear whether the cost analysis presented here is relevant . It should be noted that AV node reentry accounts for approximately 60% of paroxysmal supraventricular tachycardias and that orthodromic AV reciprocating tachycardia using a concealed accessory pathway accounts for approximately 30% of paroxysmal supraventricular tachycardias (1) (2) (3) . A prior study (9) demonstrated that the charges associated with radiofrequency catheter ablation of accessory pathways is approximately 515,000, very similar to the charges associated with radiotrequency modification of the AV node . Therefore, although the clinician may often not know the exact mechanism of paroxysmal supraventricular tachycardia, the cost analysis presented in this study will apply to the vast majority of patients with this disorder.
Conclusions . In patients who respond well to pharmacy logic therapy, the cumulative charges for medications and an annual office visit and ECG would exceed the charges for radiofrequency modification of the AV node after approximately 15 to 60 years, depending on the particular medication used. In younger patients who may require treatment for >20 to 30 years, radiofrequency modification of the AV node would be less expensive over the long-term than would therapy with medications such as atenotol, quinidine gluconate, flecainide and verapamil . Therefore, in many patients in whom AV node reentrant tachycardia is controlled but •. oho may prefer definitive therapy as en arernatne to life-long pharmacologic therapy, radiofrequency modificaticn of the AV node will also provide a long-term economic advantage .
In patients who do not respond well to pharmacologic therapy and who experience episodes of" node reentrant tachycardia that require termination with intravenous medication, the economic advantage of definitive therapy is more dramatic. In patients who must visit an emergency room once a year, the cumulative charges will exceed the charges associated with radiofrequency modification after approximately IO years. However, in patients such as those in this study, who require several emergency room visits each year, the charges related to mdiofrequency modification of the AV node may be exceeded after only 2 years . In such patients, definitive catheter therapy provides not only important clinical benefits, but also results in major long-term cost savings.
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